|
|
|
|
Inspire Announces Webcast of Presentation at BIO CEO Conference
DURHAM, N.C.--(BUSINESS WIRE)--Inspire Pharmaceuticals, Inc.(NASDAQ: ISPH) announced today that Inspire senior management will present at the BIO CEO & Investor Conference Tuesday, February 9, 2010 at 11:00 am ET in New York City. The webcast of the...
|
|
|
Inspire Announces Webcast of Presentation at BIO CEO Conference
Companies mentioned in this article: Inspire Pharmaceuticals, Inc.DURHAM, N.C. -- (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Inspire senior management will present at the BIO CEO & Investor Conference Tuesday...
|
|
|
Company Financials: Inspire Pharmaceuticals
Published By: Datamonitor Order Code: R313-61762 Description Introduction The Company Financials offers insights into the financial performance of the company over last five years for about 1000 leading global companies.The datapack covers wealth of...
|
|
|
New drugs, surgical techniques mitigate ocular surface disease
Physicians should consider more aggressive perioperative treatment of dry eye and blepharitis.Matt Hasson New topical agents including antibiotics, anti-allergy agents and steroids and off-label dosing protocols have been shown to improve the treatment of...
|
|
|
New drugs, surgical techniques mitigate ocular surface disease
Physicians should consider more aggressive perioperative treatment of dry eye and blepharitis.New topical agents including antibiotics, anti-allergy agents and steroids and off-label dosing protocols have been shown to improve the treatment of ocular surface...
|
|
|
Wedbush Maintains a 'Neutral' on Inspire Pharmaceuticals (ISPH); Lowers PT & Estimates
Wedbush maintains a 'Neutral' on Inspire Pharmaceuticals, Inc.(Nasdaq: ISPH), lowers price target from $15 to $12. Wedbush analyst says, "In addition to removing prolacria and the rho kinase inhibitor for glaucoma from our sales estimates, we have reduced...
|
|
|
Novel therapeutics demonstrate effective treatment for blepharitis
KOLOA, Hawaii Both 1% azithromycin ophthalmic solution and tobramycin 0.3%/dexamethasone 0.05% ophthalmic suspension have been shown effective in treating blepharitis and should be considered in clinical practice, a speaker here said.At Hawaiian Eye 2010,...
|
|
|
All Focus on Denufosol; Inspire's Prolacria Misses in Dry Eye Trial
Inspire Pharmaceuticals Inc.said it plans to sit down with partner Allergan Inc. after a Phase III trial of Prolacria (diquafosol tetrasodium ophthalmic solution) missed its endpoints, but it could be the end of the road for the drug, which has twice...
|
|
|
Inspire Announces Results of Phase 3 PROLACRIA Trial for Dry Eye
- Primary and Secondary Endpoints Not Met - We have provided the top-line results from this trial to our partner Allergan and we will be conducting a thorough review of the program before determining next steps, if any, stated Christy L.Shaffer, Ph. D.,...
|
|
|
Inspire Announces Results of Phase 3 PROLACRIA Trial for Dry Eye
Inspire Pharmaceuticals, Inc.(NASDAQ: ISPH) announced today that its Phase 3 clinical trial (Trial 03-113) of PROLACRIA (diquafosol tetrasodium ophthalmic solution) 2% for the treatment of dry eye disease did not meet its primary endpoint (p = 0.526) or its...
|
|
|
Inspire Pharmaceuticals shares fall on negative study results for dry eye disease drug
NEW YORK Shares of Inspire Pharmaceuticals tumbled 12 percent Thursday after the company said its drug for dry eye disease failed to meet key treatment goals in a late-stage study.The six-week study involved 490 patients. The company said it is reviewing...
|
|
|
Inspire Announces Results of Phase 3 PROLACRIA„ Trial for Dry Eye
Inspire Pharmaceuticals, Inc.(NASDAQ: ISPH) announced today that its Phase 3 clinical trial (Trial 03-113) of PROLACRIA„ (diquafosol tetrasodium ophthalmic solution) 2% for the treatment of dry eye disease did not meet its primary endpoint (p = 0...
|
|
|
Inspire Announces Results of Phase 3 PROLACRIA Trial for Dry Eye
DURHAM, N.C.(Business Wire) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that its Phase 3 clinical trial (Trial 03-113) of PROLACRIA (diquafosol tetrasodium ophthalmic solution) 2% for the treatment of dry eye disease did not meet its...
|
|
|
Inspire Announces Results of Phase 3 PROLACRIA Trial for Dry Eye
Inspire Pharmaceuticals, Inc.(NASDAQ: ISPH) announced today that its Phase 3 clinical trial (Trial 03-113) of PROLACRIA (diquafosol tetrasodium ophthalmic solution) 2% for the treatment of dry eye disease did not meet its primary endpoint (p = 0.526) or its...
|
|
|
Inspire Announces Results of Phase 3 PROLACRIA Trial for Dry Eye
Inspire Pharmaceuticals, Inc.ISPH announced today that its Phase 3 clinical trial (Trial 03-113) of PROLACRIA (diquafosol tetrasodium ophthalmic solution) 2% for the treatment of dry eye disease did not meet its primary endpoint (p = 0.526) or its secondary...
|
|
|
Inspire Announces Results of Phase 3 PROLACRIA Trial for Dry Eye
DURHAM, N.C.--(BUSINESS WIRE)--Inspire Pharmaceuticals, Inc.(NASDAQ: ISPH - News) announced today that its Phase 3 clinical trial (Trial 03-113) of PROLACRIA (diquafosol tetrasodium ophthalmic solution) 2% for the treatment of dry eye disease did not meet...
|
|
|
Delivery vehicle leads to increased bioavailability of azithromycin
Azithromycin 1% ophthalmic solution (AzaSite, Inspire Pharmaceuticals) is more soluble and able to remain on the ocular surface for a longer period than it Delivery vehicle leads to increased bioavailability of azithromycin.
|
|
|
Inspires Dry Eye and Blepharitis Trials Underway
Inspire Pharmaceuticals, Inc.(Durham, NC), completed patient enrollment for two of the companys latestage clinical trialsProlacria (diquafosol tetrasodium ophthalmic solution 2%) for the treatment of dry eye and AzaSite (azithromycin ophthalmic...
|
|
|
Inspires Dry Eye and Blepharitis Trials Underway
Inspire Pharmaceuticals, Inc.(Durham, NC), completed patient enrollment for two of the companys latestage clinical trialsProlacria (diquafosol tetrasodium ophthalmic solution 2%) for the treatment of dry eye and AzaSite (azithromycin ophthalmic...
|
|
|
Inspire Announces Webcast of Presentation at J.P. Morgan Healthcare Conference
- Inspire Pharmaceuticals, Inc.(NASDAQ:ISPH) announced today that Inspire senior management will present at the 28th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2010 at 12:00 pm local time in San Francisco, CA. The webcast of the...
|
|
|
Inspire Announces Webcast of Presentation at J.P. Morgan Healthcare Conference
DURHAM, N.C.-- (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that Inspire senior management will present at the 28th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2010 at 12:00 pm local time in San...
|
|
|
Inspire Announces Webcast of Presentation at Piper Jaffray Health Care Conference
- Inspire Pharmaceuticals, Inc.(NASDAQ: ISPH) announced today that Christy L. Shaffer, Ph. D., President and CEO, and Thomas R. Staab, II, CFO and Treasurer, will present at the 21st Annual Piper Jaffray Health Care Conference on Wednesday, December 2,...
|
